Nectero Medical has received FDA clearance to begin a Phase II/III clinical trial for their Nectero EAST® System, which aims to treat small- to mid-sized abdominal aortic aneurysms.
In an exciting development, Nectero Medical, a clinical-stage biotechnology company focused on improving the lives of patients with aneurysmal disease, announced that they have been granted Investigational New Drug (IND) clearance by the FDA. This clearance allows them to move forward with a prospective, multi-center, randomized clinical trial called the stAAAble Study. The trial will evaluate the safety and effectiveness of their innovative treatment option known as the Nectero Endovascular Aneurysm Stabilization Treatment (Nectero EAST®). The study will specifically focus on patients with infrarenal abdominal aortic aneurysms (AAAs) ranging in size from 3.5cm to 5.0cm in diameter.